NCT03352869 is a Phase 4 clinical trial of Exenatide in Polycystic Ovary Syndrome, sponsored by RenJi Hospital.

Who is sponsoring NCT03352869?

NCT03352869 is sponsored by RenJi Hospital.

What drugs are being tested in NCT03352869?

Interventions in NCT03352869: Exenatide, Metformin.

What condition does NCT03352869 study?

NCT03352869 studies Polycystic Ovary Syndrome, Overweight and Obesity, Disorder of Glucose Regulation.

Is NCT03352869 still recruiting?

NCT03352869 is currently completed. Last updated 11 September 2019.

Last reviewed 2019-09-11 · How we verify

NCT03352869

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Research of Exenatide for Overweight/Obese PCOS Patients With IGR

Completed Phase 4 Last updated 11 September 2019

What this trial tests

Phase 4 trial testing Exenatide in Polycystic Ovary Syndrome in 183 participants. Completed in 31 July 2018.

Timeline

28 November 2017

Primary endpoint
1 July 2018

31 July 2018

Quick facts

Lead sponsor	RenJi Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	183
Start date	28 November 2017
Primary completion	1 July 2018
Estimated completion	31 July 2018
Sites	1 location across China

Drugs / interventions tested

Exenatide (EXENATIDE) — full drug profile →
Metformin (metformin) — full drug profile →

Conditions studied

Polycystic Ovary Syndrome — all drugs for Polycystic Ovary Syndrome →
Overweight and Obesity — all drugs for Overweight and Obesity →
Disorder of Glucose Regulation — all drugs for Disorder of Glucose Regulation →

Sponsor

RenJi Hospital

Who can join

Adults 18 to 45, female only, with Polycystic Ovary Syndrome or Overweight and Obesity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Compare the therapeutic effects of exenatide, metformin and their combination for 3 months on reproductive and metabolic improvements of overweight/obese PCOS patients with impaired glucose regulation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
Tao T, Zhang Y, Zhu YC, Fu JR, et al · · 2021 · cited 36× · PMID 32995892 · DOI 10.1210/clinem/dgaa692

Verify or expand the search:

Other trials of Exenatide

Trials testing the same drug.

NCT05663515 — A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated E · recruiting
NCT06252623 — Exenatide For Reducing the Reinforcing Effects of Cocaine · Phase 1 · withdrawn
NCT02586831 — Diabetes Islet Preservation Immune Treatment · Phase 1, PHASE2 · withdrawn
NCT05482789 — Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes · Phase 4 · recruiting
NCT04909333 — Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia · NA · completed

Other recruiting trials for Polycystic Ovary Syndrome

Currently open trials in the same condition.

NCT07591246 — Efficay of Physical Activity Program in PCOS Females With Fatty Pancrease and Thyroid Hypofunction · NA · recruiting
NCT07446985 — Is There a Benefit From Addition of Physical Exercise to Diet Restriction/Limitation in PCOS Women With Asthma? · NA · recruiting
NCT07385716 — Evaluation of the Effect of Time-Restricted Feeding and Mediterranean Diet Model in Women With Polycystic Ovary Syndrome · NA · recruiting
NCT07366944 — PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes · NA · recruiting
NCT07289399 — Is There a Benefit From Addition of Treadmill Walking to Diet Restriction in Psoriasis Women With PCOS? · NA · recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03352869 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 11 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03352869.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing